
Harvard thought it had a cheap copy of the Magna Carta. It turned out to be extremely rare
BOSTON — Harvard University for decades assumed it had a cheap copy of the Magna Carta in its collection, a stained and faded document it had purchased for less than US$30.
But two researchers have concluded it has something much more valuable — a rare version from 1300 issued by Britain's King Edward I.
The original Magna Carta established in 1215 the principle that the king is subject to law, and it has formed the basis of constitutions globally. There are four copies of the original and, until now, there were believed to be only six copies of the 1300 version.
'My reaction was one of amazement and, in a way, awe that I should have managed to find a previously unknown Magna Carta,' said David Carpenter, a professor of medieval history at King's College London. He was searching the Harvard Law School Library website in December 2023 when he found the digitized document.
'First, I'd found one of the most rare documents and most significant documents in world constitutional history,' Carpenter said. 'But secondly, of course, it was astonishment that Harvard had been sitting on it for all these years without realizing what it was.'
Confirming the document's authenticity
Carpenter teamed up with Nicholas Vincent, a professor of medieval history at Britain's University of East Anglia, to confirm the authenticity of Harvard's document.
Comparing it to the other six copies from 1300, Carpenter found the dimensions matched up. He and Vincent then turned to images Harvard librarians created using ultraviolet light and spectral imaging. The technology helps scholars see details on faded documents that are not visible to the human eye.
That allowed them to compare the texts word-for-word, as well as the handwriting, which include a large capital 'E' at the start in 'Edwardus' and elongated letters in the first line.
After the 1215 original printed by King John, five other editions were written in the following decades — until 1300, the last time the full document was set out and authorized by the king's seal.
The 1300 version of Magna Carta is 'different from the previous versions in a whole series of small ways and the changes are found in every single one,' Carpenter said.
Harvard had to meet a high bar to prove authenticity, Carpenter said, and it did so 'with flying colors.'
Its tattered and faded copy of the Magna Carta is worth millions of dollars, Carpenter estimated — though Harvard has no plans to sell it. A 1297 version of the Magna Carta sold at auction in 2007 for $21.3 million.
A document with a colourful history
The other mystery behind the document was the journey it took to Harvard.
That task was left to Vincent, who was able to trace it all the way back to the former parliamentary borough of Appleby in Westmorland, England.
The Harvard Law School library purchased its copy in 1946 from a London book dealer for $27.50. At the time, it was wrongly dated as being made in 1327.
Vincent determined the document was sent to a British auction house in 1945 by a World War I flying ace who also played a role defending Malta in World War II. The war hero, Forster Maynard, inherited the archives from Thomas and John Clarkson, who were leading campaigners against the slave trade. One of them, Thomas Clarkson, became friends with William Lowther, hereditary lord of the manor of Appleby, and he possibly gave it to Clarkson.
'There's a chain of connection there, as it were, a smoking gun, but there isn't any clear proof as yet that this is the Appleby Magna Carta. But it seems to me very likely that it is,' Vincent said. He said he would like to find a letter or other documentation showing the Magna Carta was given to Thomas Clarkson.
Making Magna Carta relevant for a new generation
Vincent and Carpenter plan to visit Harvard in June to see its Magna Carta firsthand — and they say the document is as relevant as ever at a time when Harvard is clashing with the Trump administration over how much authority the federal government should have over its leadership, admissions and activism on campus.
'It turns up at Harvard at precisely the moment where Harvard is under attack as a private institution by a state authority that seems to want to tell Harvard what to do,' Vincent said.
It also is a chance for a new generation to learn about the Magna Carta, which played a part in the founding of the United States — from the Declaration of Independence to the adoption of the Bill of Rights. Seventeen states have incorporated aspects of it into their laws.
'We think of law libraries as places where people can come and understand the underpinnings of democracy,' said Amanda Watson, the assistant dean for library and information services at Harvard Law School. 'To think that Magna Carta could inspire new generations of people to think about individual liberty and what that means and what self-governance means is very exciting.'
Michael Casey, The Associated Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


National Post
an hour ago
- National Post
IQM to Integrate Quantum Computer Into Oak Ridge National Laboratory's HPC Systems
IQM Radiance 20-qubit upgradeable full stack superconducting quantum computer will be the first on-premises quantum computer at Oak Ridge National Laboratory (ORNL). The system will be delivered by the third quarter of 2025, and it will be integrated with ORNL's high-performance computing (HPC) systems to advance hybrid quantum-classical application development. Article content Article content TENNESSEE, USA & ESPOO, Finland — The Department of Energy's Oak Ridge National Laboratory (ORNL) today announced it has selected IQM Radiance as its first-ever purchased on-premises quantum computer to be integrated into high-performance computing (HPC) systems at ORNL. Article content Article content IQM Radiance 20-qubit quantum computer is based on superconducting technology and aimed at accelerating hybrid quantum-classical application development. The quantum computer will be delivered by the third quarter of 2025 and is upgradeable to higher qubit counts in the future. Article content Acquiring an on-premises IQM Radiance supports ORNL's mission to work towards seamless, tight integration between quantum computing hardware and HPC infrastructure. ORNL's teams have been recognised for leading quantum-HPC integration efforts in the research community for years. Article content Today's announcement follows an earlier announcement of ORNL's Quantum Computing User Program (QCUP) leveraging the IQM Resonance cloud platform for advanced quantum research. Article content 'ORNL has a decades-long history in high-performance computing and is today one of the leading research institutions in the US for quantum computing,' said Travis Humble, advisor to the QCUP and director of the Quantum Science Center at ORNL. 'IQM's on-premises installation will allow our researchers hands-on access to cutting-edge quantum computing technology as we explore how quantum computers will be integrated with HPC systems to tackle early quantum advantage.' Article content 'We are excited that ORNL has selected IQM Radiance as their first-ever purchased on-premises quantum computer,' said Mikko Välimäki, Co-CEO of IQM Quantum Computers. 'This further proves that quantum computers are already today highly useful and in demand. Important research can be done to integrate quantum computers with classical hardware and develop the platform for quantum advantage.' Article content Since entering the US market, IQM has been leveraging its leading global market position, state-of-the-art technology, and partnerships to drive quantum research, adoption and education. Article content 'We are committed to supporting ORNL's pioneering efforts to advance quantum computing across the US. Our shared vision to accelerate the integration of quantum and HPC infrastructure has made this journey incredibly rewarding, and we are just getting started. Our long-term goal is to collaborate closely with ORNL's researchers in quantum application areas like fluid dynamics, particle physics and electronic structure simulations,' said Jan Goetz, co-founder and co-CEO of IQM. Article content About IQM Quantum Computers: Article content IQM is a global leader in superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its computers. IQM customers include the leading high-performance computing centres, research labs, universities and enterprises which have full access to IQM's software and hardware. IQM has over 300 employees with headquarters in Finland and a global presence in France, Germany, Italy, Japan, Poland, Spain, Singapore, South Korea and the United States. Article content Article content Article content Article content Article content Contacts Article content Media contact: Article content Article content Email: Article content Article content

National Post
4 hours ago
- National Post
Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025
Article content LEXINGTON, Mass. — Agenus Inc. ('Agenus') (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments that could shape the future of cancer treatment. The agenda includes a strategic and financial overview, achievements tied to the Zydus partnership closing, patient needs fueling interest in colorectal cancer (CRC) studies, recent data from the botensilimab (BOT) and balstilimab (BAL) program, and an overview of the Phase 3 BATTMAN study in metastatic CRC—plus highlights of upcoming milestones and potential breakthroughs in immuno-oncology. The session will conclude with a live Q&A. Article content Speakers to Include: Article content Article content Garo H. Armen, PhD Article content Founder, Chairman, CEO of Agenus Article content Jennifer Buell, PhD CEO of MiNK Therapeutics/ Chair of Executive Committee of Agenus Article content Richard M. Goldberg, MD Chief Development Officer of Agenus (joined May 2025) GI oncology expert with 40+ years in CRC research Article content Nicholas C. DeVito, MD Assistant Professor of Medical Oncology at Duke University Primarily treats patients with CRC and gastroesophageal cancers Research focused on tumor immune evasion and immunotherapy Article content Chris O'Callaghan, DVM, MSc, PhD, & Jonathan Loree, MD, MS, FRCPC (CCTG): Senior Investigators at Canadian Cancer Trials Group (CCTG) Stakeholder Briefing Details: Webcast Link | Audience Conference Call Registration Link | Conference ID: 73242 Article content About Agenus Article content Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels. Article content About Botensilimab (BOT) Article content Botensilimab is a multifunctional, human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to 'cold' tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses. Article content Botensilimab alone, or in combination with Agenus' investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. Approximately 1,200 patients have been treated across the botensilimab/balstilimab program in phase 1 and phase 2 clinical trials. For more information about botensilimab trials, visit Article content About Balstilimab (BAL) Article content Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types. Article content Forward-Looking Statements Article content This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the botensilimab and balstilimab clinical programs, expected trial initiations and regulatory plans, and the potential benefits of the combination therapy. Words such as 'may,' 'believes,' 'expects,' 'anticipates,' 'hopes,' 'intends,' 'plans,' 'forecasts,' 'estimates,' 'will,' 'potential,' 'game-changing,' 'curative,' and similar expressions are intended to identify forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. Factors that could cause actual results to differ include, but are not limited to, those described under the 'Risk Factors' section of Agenus' most recent Annual Report on Form 10-K for 2024 and subsequent Quarterly Reports on Form 10-Q filed with the SEC. Agenus cautions investors not to place undue reliance on forward-looking statements in this release, which speak only as of the date of this announcement. The company undertakes no obligation to update or revise these statements, except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Article content Article content Article content Article content Contacts Article content Investors Article content Article content 917-362-1370 |


Globe and Mail
5 hours ago
- Globe and Mail
Exact Sciences to Participate in September Investor Conferences
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Wells Fargo Healthcare Conference, Boston Fireside chat on Wednesday, September 3, 2025 at 1:30 p.m. ET Baird Global Healthcare Conference, New York Fireside chat on Tuesday, September 9, 2025 at 10:50 a.m. ET The webcast can be accessed in the investor relations section of Exact Sciences' website at About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company's growing portfolio includes well-established brands such as Cologuard® and Oncotype DX®, along with innovative solutions like Oncodetect™ for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.